Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/104397METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS
WO 28.05.2020
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/EP2019/081692 Applicant BIOASTER Inventor LECINE, Patrick
The present invention concerns a support for a multiplex binding experiment functionalized with at least two different polypeptides having high affinity to their cognate binding partners provided in a reaction mixture, and their use in e.g. immunoassays.
2.WO/2020/104577USE OF BACTERIAL EXTRACELLULAR VESICLES AS A BIOMARKER FOR INTESTINAL BARRIER PERMEABILITY AND MICROBIAL DYSBIOSIS
WO 28.05.2020
Int.Class C12Q 1/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Appl.No PCT/EP2019/082054 Applicant UNIVERSITEIT GENT Inventor HENDRIX, An
The present invention relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), said method comprising the steps of a) extracting bacterial EV from said biofluid, b) analyzing said bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein said disease marker is a disease-specific molecular pattern of said subject; and said subject comprising patients diagnosed with HIV, IBD or cancer or said subject receiving a treatment.
3.WO/2020/105567IMMUNO-CHROMATOGRAPHY TEST STRIP AND IMMUNO-CHROMATOGRAPHY DETECTION KIT
WO 28.05.2020
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/JP2019/044997 Applicant SEKISUI MEDICAL CO., LTD. Inventor ITOU Kanako
The present invention addresses the problem of providing an immuno-chromatography test strip having a conjugate held therein which is rapidly eluted due to the passage of a test liquid so as to be able to react with a substance to be detected, wherein the amount of the conjugate contributing to the reaction varies little, and wherein variations of the values measured can be prevented. The present invention provides an immuno-chromatography test strip having a porous membrane comprising at least a sample supply section, a deployment section, and a detection section. In a portion of the deployment section, a conjugate containing a specific binding substance labeled with a labeling substance is held, along with glucose and/or maltose, in an elutable and dry state.
4.WO/2020/106577USE OF NATURAL-ABUNDANCE STABLE ISOTOPES AND DNA GENOTYPING FOR IDENTIFYING BIOLOGICAL PRODUCTS
WO 28.05.2020
Int.Class G16B 25/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
25ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Appl.No PCT/US2019/061745 Applicant JASPER, John, P. Inventor JASPER, John, P.
The combined use of natural-abundance stable-isotopic analysis of bulk materials and DNA genotyping of biological materials is a highly-specific (~1 :1 x 1017) fingerprinting method for identifying such products in supply chains.
5.WO/2020/107037COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
WO 28.05.2020
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
Appl.No PCT/US2019/063113 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor MORDES, Daniel, A.
Disclosed are compounds and methods for treating diseases and conditions related to toxic dipeptide repeats including Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD). Also disclosed are method of screening for agents that treat or prevent diseases and conditions related to toxic dipeptide repeats.
6.WO/2020/105626MARKER FOR PREDICTING PROGNOSIS OF PANCREATIC TUMOR
WO 28.05.2020
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/JP2019/045244 Applicant KANSAI MEDICAL UNIVERSITY EDUCATIONAL CORPORATION Inventor ISHIDA, Mitsuaki
The present invention addresses the problem of providing a biomarker which enables prediction of the prognosis of a patient with a tumor on the basis of the nature of tumor cells themselves. In the present invention, the prognosis of a pancreatic tumor of a subject is predicted by a method for detecting a marker for predicting the prognosis of a pancreatic tumor, the method comprising the step of detecting adipophilin in pancreatic tumor cells collected from the subject.
7.WO/2020/106556DIELECTRIC SPECTROSCOPY SENSING APPARAUS AND METHOD OF USE
WO 28.05.2020
Int.Class G01N 33/487
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
Appl.No PCT/US2019/061613 Applicant XATEK, INC. Inventor ERTEL, Jason, R.
A DS sensing apparatus includes a body and electrodes provided on the body. The body defines a test volume between a first surface and an opposing second surface spaced from the first surface a distance that allows a fluid to enter the test volume from a fluid inlet, which is communicatively coupled to the test volume, via capillary action. The electrodes include a first sensing electrode on the first surface and configured to receive an input RF signal, a second sensing electrode on the first surface spaced from the first sensing electrode and configured to deliver an output RF signal and a floating electrode on the second surface.
8.WO/2020/104705PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE
WO 28.05.2020
Int.Class G01N 33/564
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
564for pre-existing immune complex or autoimmune disease
Appl.No PCT/EP2019/082483 Applicant KATHOLIEKE UNIVERSITEIT LEUVEN Inventor VERMEIRE, Séverine
In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti- α4β7-intcgrin agents and/or anti- IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.
9.WO/2020/102874COMPOUND, USE, PHARMACEUTICAL COMPOSITION, METHOD OF DIAGNOSIS, METHOD OF TREATMENT, AND METHOD OF TRANSPORTATION AND/OR INTERNALIZATION OF A COMPOUND INTO EUKARYOTIC CELLS
WO 28.05.2020
Int.Class C07K 14/435
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
Appl.No PCT/BR2019/050501 Applicant INSTITUTO BUTANTAN Inventor TAVASSI, Ana Marisa Chudzinski
The invention pertains to the technical fields of pharmaceutical sciences, immunology, diagnosis and/or treatment of cancer. Specifically, the invention relates to peptides derived from the C-terminal portion of the tick amblyomin-X protein, said peptides being intended for targeting or promoting the internalization of molecular entities into the intracellular domain of eukaryotic or neoplastic cells. The invention also relates to the use of said peptides for modifying other pharmaceutically active ingredients, to a pharmaceutical composition comprising said peptides and to a method of diagnosis, prognosis and/or treatment of cancer or other cell-altering conditions.
10.WO/2020/104294METHOD FOR PREDICTING THE CLINICAL RESPONSE OF ONCOLYTIC PARVOVIRUS H1 (H-1PV) TREATMENT IN A PATIENT SUSPECTED OF SUFFERING FROM CANCER BY MEASURING THE EXPRESSION LEVELS OF LAMININS AND/OR GALECTINS AS BIOMARKERS IN A PATIENT´S SAMPLE
WO 28.05.2020
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/EP2019/081368 Applicant DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS Inventor MARCHINI, Antonio
The present invention concerns the use of laminins and/or galectins as biomarker(s) for predicting the outcome of the treatment with oncolytic parvovirus H1 (H-1PV) in a cancer patient.